FDA Safer Technologies Program (STeP) for Medical Devices: Complete Regulatory Guide

Executive Summary: The Safety-First Expedited Pathway

Device manufacturers developing safety-enhancing medical technologies often find themselves in a regulatory gap. While the high-profile FDA Breakthrough Devices Program offers substantial benefits—such as prioritized review and interactive communication—it is strictly limited to devices treating or diagnosing "life-threatening or irreversibly debilitating" conditions. For devices that significantly improve safety but target less severe, non-life-threatening conditions, the Breakthrough pathway is unavailable.

To address this gap, the FDA established the Safer Technologies Program (STeP). Modelled directly on the Breakthrough Devices Program, STeP is a voluntary program designed to expedite the development, assessment, and review of medical devices and device-led combination products that are reasonably expected to significantly improve the safety of currently available treatments or diagnostics.

Direct Decision Brief

If your device significantly improves the safety of an existing treatment for a serious but not life-threatening condition, it is highly likely that the device does not qualify for the Breakthrough Devices Program. Instead, the Safer Technologies Program (STeP) is your primary expedited review option.

To determine if STeP is worth pursuing, consider this direct decision test:

1. Premarket Pathway: Is the device subject to a 510(k) premarket notification, a De Novo classification request, or a Premarket Approval (PMA) application?
2. Breakthrough Exclusivity: Is the target condition serious, but not to the level of being life-threatening or irreversibly debilitating (disqualifying the device from Breakthrough)?
3. Safety Innovation: Can you demonstrate a reasonable expectation that the device will significantly improve the benefit-risk profile by reducing a known serious adverse event, reducing a device failure mode, reducing a use error, or improving the safety of another intervention?
4. Resources vs. Timeline: Are you prepared to compile a comprehensive Q-Submission request for inclusion, navigate a 60-day FDA decision cycle, and actively participate in interactive review and sprint discussions, knowing that STeP does not offer the same automatic Medicare reimbursement linkages as the Breakthrough program?

Sponsors apply for STeP by submitting a formal Q-Submission. The FDA aims to request additional information within 30 days and issue a final decision (inclusion or denial) within 60 days of the submission date. Once included, sponsors gain access to collaborative mechanisms, including sprint discussions and early input on Data Development Plans (DDP).

---

What Is the FDA Safer Technologies Program (STeP)?

The FDA Safer Technologies Program (STeP) represents a major evolution in the agency's approach to expedited product review. Officially established on January 6, 2021, under docket FDA-2019-D-4048, the FDA issued its final guidance document, "Safer Technologies Program for Medical Devices", following a public comment period. The program became fully operational and began accepting formal requests for inclusion on March 8, 2021, after a 60-day operationalization window.

The statutory foundation of STeP lies within the FDA's general authority under the Federal Food, Drug, and Cosmetic (FD&C) Act to facilitate the development and review of medical devices. While the Breakthrough program was explicitly mandated by Congress under Section 515B of the FD&C Act (via the 21st Century Cures Act), STeP was developed as an administrative policy expansion to capture safety-first innovations that fell outside the Breakthrough program's narrow therapeutic scope.

STeP is administered by the Center for Devices and Radiological Health (CDRH) and the Center for Biologics Evaluation and Research (CBER). It applies to:

• Medical devices (Class II and Class III)
• Device-led combination products where the device constituent part is responsible for the primary safety benefit

The program is voluntary, and participation does not alter the statutory standards for marketing authorization. A device in STeP must still demonstrate safety and effectiveness (PMA) or substantial equivalence to a predicate (510(k)) or a reasonable assurance of safety and effectiveness (De Novo).

---

Key Differences: STeP vs. Breakthrough Devices Program

Understanding the boundaries between STeP and the Breakthrough Devices Program is essential for any regulatory strategy. While the operational benefits (such as interactive review and prioritized timing) are similar, the entry criteria and strategic implications differ.

The following matrix compares the core parameters of both programs:

Feature/Parameter	FDA Breakthrough Devices Program	FDA Safer Technologies Program (STeP)
Establishment Date	December 2018 (Final Guidance)	January 6, 2021 (Final Guidance, Docket FDA-2019-D-4048)
Statutory Basis	FD&C Act Section 515B (21st Century Cures Act)	FDA Administrative Policy & Program Expansion
Target Conditions	Life-threatening or irreversibly debilitating diseases/conditions	Serious, but non-life-threatening or non-irreversibly debilitating conditions
Primary Qualifier	Represents a "more effective" treatment or diagnosis	Offers a "significant safety improvement"
Premarket Pathways	510(k), De Novo, PMA	510(k), De Novo, PMA
Inclusion Request	Q-Submission (Designation Request)	Q-Submission (Inclusion Request)
FDA Decision Timeline	60 days (30 days for additional info)	60 days (30 days for additional info)
Uptake Scale (Metrics)	1,246 designations (through Dec 31, 2025)	Small fraction of Breakthrough volume
TAP Pilot Inclusion	Yes (CDRH TAP Pilot)	Yes (Inclusion starting in MDUFA V, FY 2026-2027)
Medicare Linkage	Strong (Proposed MCIT / TCET / RAPID pathways)	None (No automatic national coverage linkages)

The Critical Severity Distinction

The primary differentiator is the severity of the target disease or condition. The FDA defines a condition as life-threatening if the likelihood of death is high unless the course of the disease is interrupted. It defines a condition as irreversibly debilitating if it causes serious, permanent deterioration of health or function that cannot be reversed.

If your device treats a condition that is serious but does not meet this threshold, it is ineligible for the Breakthrough program. Examples of "serious" conditions suitable for STeP include:

• Osteoarthritis of the knee (not irreversibly debilitating, but serious and painful)
• Moderate, chronic urinary incontinence
• Mild to moderate depression (without active suicidal ideation)
• Surgical site infection risks in routine elective procedures
• Non-invasive monitoring in non-intensive care settings

If a device targets a condition that is borderline, the sponsor should evaluate if they can support the "irreversibly debilitating" standard. If they cannot, they must steer toward STeP.

---

Recommended Reading

FDA Medical Device Product Codes: Analysis of 7,075 Classification Codes

Regulatory 510(k)2026-07-14 · 16 min read

Detailed Eligibility Criteria for STeP

To be accepted into the Safer Technologies Program, a medical device or device-led combination product must satisfy a two-factor eligibility test. The first factor ensures the device targets appropriate conditions, while the second factor evaluates the safety innovation itself.

Factor 1: The Condition and Pathway Test

The device must satisfy two criteria under Factor 1:

1. Pathway Eligibility: The device must be subject to review under a premarket notification (510(k)), a De Novo classification request, or a Premarket Approval (PMA) application. Devices subject to Humanitarian Device Exemptions (HDE) or product development protocols are generally not eligible.
2. Breakthrough Ineligibility: The device must target a disease or condition that is serious, but not to the extent of being life-threatening or irreversibly debilitating. This is a negative constraint; if a device qualifies for the Breakthrough program, it cannot be accepted into STeP.

Factor 2: The Significant Safety Improvement Test

The core of a STeP request is demonstrating a reasonable expectation that the device will significantly improve the benefit-risk profile of a treatment or diagnostic option. This improvement must be driven by a substantial safety innovation.

The FDA final guidance outlines four specific safety-improvement criteria. A device must satisfy at least one of these:

1. Reduce the occurrence or severity of a known serious adverse event

This criterion applies to devices designed to prevent or mitigate severe complications associated with established medical interventions.

• Example: A vascular closure device that incorporates a novel mechanical seal to significantly reduce the risk of access-site hematoma and major bleeding compared to manual compression or existing closure systems.
• Evidence required: Data showing the device's mechanism of action effectively prevents vascular damage, supported by bench testing and historical adverse-event rates of the comparator.

2. Reduce the occurrence or severity of a known device failure mode

This criterion applies to modifications of existing device designs that eliminate or minimize critical failure mechanisms that lead to patient harm or surgical revision.

• Example: An orthopedic joint replacement implant that utilizes a new wear-resistant polymer matrix, significantly reducing the rate of aseptic loosening and subsequent revision surgery.
• Evidence required: Extended wear testing, fatigue resistance data, and particulate analysis demonstrating a substantial reduction in debris-induced osteolysis compared to standard ultra-high-molecular-weight polyethylene.

3. Reduce the occurrence or severity of a known use-related hazard or use error

This criterion focuses on human factors and usability engineering. It is highly relevant for devices used in complex clinical environments or by patients at home, where use errors can lead to critical harm.

• Example: An insulin infusion pump or home-use hemodialysis system with an advanced user interface, integrated sensors, and automated lockout features that prevent accidental dosing errors or incorrect connections.
• Evidence required: Comparative usability testing, user error analysis, and simulated-use studies demonstrating that typical operators are significantly less likely to commit critical tasks errors.

4. Improve the safety of another device or intervention

This criterion applies to accessory devices or diagnostic tools that enhance the safety of an independent primary medical procedure or another medical device.

• Example: A specialized guidewire navigation sensor that provides real-time position feedback to prevent vessel perforation during interventional cardiology procedures.
• Evidence required: Validation data showing the sensor accurately detects vessel boundaries and alerts the clinician before wall damage occurs, reducing the rate of procedural perforation.

---

The STeP Application Process: Step-by-Step Guide

Gaining entry into STeP requires a structured application submitted through the FDA's Q-Submission program. The submission is known as a Request for Inclusion in the Safer Technologies Program.

Step 1: Pre-Submission Preparation and Evidence Assembly

Before drafting the submission, sponsors must compile the evidentiary basis for their safety claims. While the FDA does not require complete clinical data to grant STeP inclusion, it does require a "reasonable expectation" of a significant safety benefit. This expectation must be backed by objective evidence.

• Plausible Mechanism: You must explain the biological or mechanical basis of the safety improvement. Why does this design change reduce a failure mode or adverse event?
• Bench and Preclinical Data: Provide engineering reports, simulated-use testing, and animal study results. For instance, if you claim a reduction in use error, include preliminary human factors evaluation data.
• Comparative Baseline: Establish the baseline safety profile of currently marketed options. Use literature, FDA MAUDE database analysis, and public recalls to document the safety problems of existing therapeutic options, showing that your device addresses a real-world hazard.

Step 2: Drafting the Request for Inclusion

The Request for Inclusion should be formatted as a formal Q-Submission and must contain the following key sections:

1. Administrative Information: Clearly state that the submission is a "Request for Inclusion in the Safer Technologies Program." Specify the target premarket pathway (510(k), De Novo, or PMA) and the lead FDA review division.
2. Device Description: Provide a detailed description of the device's technology, materials, mechanism of action, and indications for use. Highlight the specific components or features that drive the safety innovation.
3. Regulatory History: Detail any prior interactions with the FDA regarding the device, including previous pre-submissions, investigational device epochs (IDEs), or premarket submissions.
4. Eligibility Argument (Factor 1): Explain why the target condition is serious but does not cross the threshold into life-threatening or irreversibly debilitating.
5. Safety Innovation Argument (Factor 2): Structure your argument around one or more of the four safety-improvement criteria. Use headings for each criterion you claim and link them directly to the compiled preclinical or clinical data.
6. Proposed Interaction Plan: Outline your proposed plan for interacting with the FDA if included, such as specific sprint discussions or data development plan review requests.

Step 3: FDA Review and the 60-Day Timeline

Once the Q-Submission is uploaded via the eSTAR portal or physical media to the Document Control Center (DCC), the FDA follows a strict review timeline:

gantt
    title FDA STeP Inclusion Review Timeline (60 Days Total)
    dateFormat  X
    axisFormat %d
    section Administrative
    DCC Receipt & Logging          :active, 0, 15
    section Additional Info
    FDA Identifies Missing Data    :crit, 15, 30
    section Substantive Review
    FDA Evaluation of Criteria     : 30, 50
    section Final Decision
    Inclusion or Denial Letter     :success, 50, 60

• Day 1 to 15 (Administrative Review): The lead division performs an initial administrative check to confirm the package is complete and the device falls under their jurisdiction.
• Day 30 (Additional Information Request): If the FDA requires clarification or minor additional data to make a decision, they intend to request this information by Day 30. The review clock is paused until the sponsor responds.
• Day 60 (Final Decision): The FDA intends to issue a final written decision by Day 60. The outcome will be either an Inclusion Letter, welcoming the sponsor into the program, or a Denial Letter, outlining why the device failed to meet the criteria.

[!IMPORTANT] If the FDA denies inclusion in STeP, the decision does not affect the device's substantive premarket review. The sponsor can still submit a standard Q-Submission or premarket application. However, they will not have access to the expedited program benefits.

---

Real-World Program Benefits: Interactive Review and Sprint Discussions

For sponsors who secure an Inclusion Letter, STeP offers several mechanisms designed to reduce the time and cost of premarket review. These benefits are provided as resources permit, meaning the FDA allocates its staff based on current workload.

1. Interactive and Timely Communications

Sponsors can communicate directly with the lead reviewer and review team through phone calls, emails, and informal virtual touchpoints. Rather than waiting for formal letters or structured pre-submission meetings (which typically take 70 to 90 days to schedule), STeP sponsors can resolve minor protocol questions or data interpretation disputes rapidly.

2. Sprint Discussions

Sprint discussions are highly focused, rapid-turnaround interactions designed to resolve specific regulatory or scientific issues. Instead of addressing the entire device dossier at once, a sponsor can request a sprint to discuss a single topic, such as:

• A biocompatibility testing protocol for a novel material
• The sample size calculation for a human factors study
• The clinical study end-point definition

The FDA and the sponsor agree on a schedule, typically resolving the issue within a 45-day window through iterative data exchanges and teleconferences. This prevents major misunderstandings from delaying the final premarket submission.

3. Data Development Plans (DDP)

A Data Development Plan (DDP) is a collaborative document that outlines the totality of clinical and non-clinical data required to support the device's marketing clearance or approval. Under STeP, the FDA work with the sponsor to draft a DDP that balances premarket and postmarket data requirements. In some cases, the FDA may permit certain data collections to be deferred to the postmarket phase, reducing the time required to clear or approve the device.

4. Senior Management Engagement

If the sponsor and the review team reach an impasse on a critical scientific or regulatory issue, STeP provides a formal mechanism for senior management engagement. This allows division directors or branch chiefs to participate early in dispute resolution, preventing lengthy delays.

5. Prioritized Review

When the sponsor finally submits their 510(k), De Novo, or PMA, the application is placed at the front of the review queue. The FDA review team is assigned immediately, and subsequent questions (such as Additional Information letters) are prioritized.

---

Recommended Reading

Certificate of Need (CON) for Medical Devices: State-by-State Guide

Regulatory Reimbursement & Market Access2026-07-22 · 21 min read

Program Metrics and Strategic Decisions

While the benefits of STeP are clear, the program's real-world utilization has been modest compared to the Breakthrough Devices Program.

The Uptake Disparity

Through December 31, 2025, the FDA had granted 1,246 Breakthrough Device designations (comprising 1,226 by CDRH and 20 by CBER) and authorized 185 Breakthrough devices for marketing. In contrast, the FDA has not published routine cumulative totals for STeP. Industry estimates indicate that STeP inclusion requests and approvals represent a tiny fraction of the Breakthrough volume.

Sponsors should understand the reasons for this low uptake before committing resources to a STeP request:

1. Reimbursement Incentives: The primary driver of Breakthrough applications is the potential for accelerated Medicare reimbursement (discussed below). STeP has no such automatic linkage, reducing its commercial appeal.
2. Evidence Threshold: Preparing a robust STeP request requires substantial preclinical data and regulatory writing. For a standard 510(k) device, the effort to get into STeP may exceed the potential time saved during the premarket review phase itself.
3. FDA Resource Constraints: Because STeP benefits are granted "as resources permit," and the Breakthrough program has statutory priority, review divisions often prioritize Breakthrough reviews over STeP interactions during peak periods.

When is STeP Worth It?

A STeP application is highly recommended in the following scenarios:

                          Is a STeP application worth the effort?
                                             |
                   -----------------------------------------------------
                   |                                                   |
           PMA or De Novo Pathway                             Standard 510(k) Pathway
                   |                                                   |
    Highly Recommended: Clear benefit                      Evaluate carefully: Often faster
    from early FDA alignment on complex                    to proceed directly to submission
    clinical trials & study designs.                       unless testing is highly novel.

• De Novo and PMA Pathways: For novel devices that face complex clinical trial designs or unique safety testing challenges, the early FDA alignment provided by STeP (especially DDPs and sprint discussions) is highly valuable.
• Novel Materials or Usability Issues: If your device incorporates a technology that the FDA has not reviewed before (e.g., a new polymer or a home-use application of a clinical device), having interactive review helps mitigate the risk of major deficiencies.
• Strategic Differentiation: For venture-backed startups, securing STeP inclusion is a validated third-party endorsement of the technology's safety potential, helping secure funding.

Conversely, for a standard, straightforward 510(k) device with clear predicates, the time spent preparing and waiting for a STeP decision (60+ days) may exceed the duration of a direct 510(k) review.

---

The TAP Pilot Integration: A Freshness Hook for FY 2026–2027

A major development in the evolution of STeP is its integration into the Total Product Life Cycle Advisory Program (TAP) pilot.

Established under the Medical Device User Fee Amendments of 2022 (MDUFA V), the TAP pilot is designed to improve medical device development and review by providing strategic alignment and early engagement between sponsors, the FDA, payers, clinicians, and patient advocates. Initially, the TAP pilot was restricted strictly to Breakthrough designated devices.

However, under the MDUFA V commitment letter, the FDA is expanding the TAP pilot to include devices with a granted Breakthrough designation or a request for inclusion in STeP during fiscal years 2026 and 2027. This represents a major shift:

• STeP sponsors can now gain access to the TAP pilot's enhanced advisory features.
• This includes early feedback from commercial payers on coverage requirements, input from specialty clinician societies on study endpoints, and patient-preference advice.
• The expansion is gradual, with a limited number of slots allocated per fiscal year.

Sponsors targeting a STeP application in 2026 or 2027 should explicitly evaluate if they can secure a TAP pilot slot, as this significantly bridges the gap between regulatory approval and commercial reimbursement.

---

Reimbursement Reality: The Missing Link

The largest hurdle for STeP-designated devices is the absence of an automatic reimbursement pathway.

For Breakthrough devices, the Centers for Medicare & Medicaid Services (CMS) has proposed and implemented various accelerated coverage pathways (such as the proposed Medicare Coverage of Innovative Technology (MCIT), the Transitional Coverage for Innovative Technology (TCET), and the FDA-CMS RAPID coverage pathway). These pathways aim to provide immediate national Medicare coverage for a period of 3 to 4 years post-market authorization.

STeP devices do not qualify for these automatic coverage pathways.

A device cleared or approved under STeP must navigate the standard US reimbursement process:

1. Coding: Secure appropriate CPT or HCPCS codes (either using existing codes or applying for new ones).
2. Coverage: Negotiate coverage policies with commercial payers and local Medicare Administrative Contractors (MACs) through the Local Coverage Determination (LCD) or National Coverage Determination (NCD) process.
3. Payment: Align the device cost with existing hospital payment systems, such as DRGs for inpatient care or APCs for outpatient services.

Strategic Coding Tip

Because STeP does not offer automatic reimbursement, sponsors must begin their reimbursement planning concurrently with their STeP application. Use the premarket phase to generate the economic and clinical utility data that payers require. Do not assume that your "FDA STeP Inclusion Letter" will influence private payers; commercial coverage decisions are driven by clinical effectiveness and cost-utility studies, not expedited FDA status.

---

Recommended Reading

Medical Device Startup Regulatory Strategy: From Concept to FDA Clearance (2026)

Regulatory 510(k)2026-04-13 · 19 min read

Frequently Asked Questions (FAQ)

Can a device that treats a life-threatening condition use STeP instead of Breakthrough?

No. The Safer Technologies Program is explicitly restricted to devices that target serious, but not life-threatening or irreversibly debilitating conditions. If your device meets the Breakthrough eligibility criteria, it is excluded from STeP. You must apply for the Breakthrough Devices Program.

Is STeP a substitute for a 510(k), De Novo, or PMA submission?

No. STeP is not a marketing authorization pathway. It is an administrative support program. A device in STeP must still prepare, submit, and clear/approve a standard 510(k), De Novo, or PMA application. The program simply provides priority review and interactive feedback to make that process faster and more predictable.

How many devices have received STeP inclusion compared with Breakthrough designations?

While the FDA has granted 1,246 Breakthrough Device designations through December 31, 2025 (1,226 from CDRH and 20 from CBER), it does not publish routine cumulative totals for STeP. Because FDA does not report a running STeP count, any figure is an estimate; what is clear from public tracking is that STeP inclusion has remained a small fraction of Breakthrough's volume, reflecting the lack of automatic Medicare reimbursement linkages and the resources required to apply.

Can a combination product apply for STeP?

Yes, device-led combination products are eligible for STeP, provided they are subject to review under a 510(k), De Novo, or PMA, and the safety innovation is primarily driven by the device constituent part of the combination product.

---

Sources

1. U.S. Food and Drug Administration (FDA), "Safer Technologies Program (SteP) for Medical Devices", Content Current March 15, 2021. Available at: FDA STeP Program Page
2. U.S. Food and Drug Administration (FDA), "Safer Technologies Program for Medical Devices; Guidance for Industry and FDA Staff", Issued January 6, 2021 (Docket FDA-2019-D-4048). Available at: FDA STeP Guidance Document
3. Federal Register, "Safer Technologies Program for Medical Devices; Guidance for Industry and Food and Drug Administration Staff; Availability", 86 FR 794, January 6, 2021. Available at: Federal Register 86 FR 794
4. U.S. Food and Drug Administration (FDA), "Breakthrough Devices Program Metrics and Marketing Authorizations", Updated February 2026 (CDRH/CBER data through December 31, 2025). Available at: FDA Breakthrough Metrics Bulletin
5. Regulatory Affairs Professionals Society (RAPS), "MDUFA V Commitment Letter and the TAP Pilot Expansion", September 2022. Available at: RAPS MDUFA V Analysis
6. Manatt, Phelps & Phillips, LLP, "FDA Issues Final Guidance on the Safer Technologies Program (STeP) for Medical Devices", January 2021. Available at: Manatt STeP Client Alert